44
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Hyaluronic acid-coated liposomes for enhanced in vivo efficacy of neogambogic acid via active tumor cell targeting and prolonged systemic exposure

, , , , &
Received 11 Dec 2023, Accepted 23 Apr 2024, Published online: 11 May 2024

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi: 10.3322/caac.21551.
  • Pal SK, Miller MJ, Agarwal N, et al. Clinical cancer advances 2019: Annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol. 2019;37(10):834–849. doi: 10.1200/JCO.18.02037.
  • Wang S, Long S, Deng Z, et al. Positive role of Chinese herbal medicine in cancer immune regulation. Am J Chin Med. 2020;48(7):1577–1592. doi: 10.1142/S0192415X20500780.
  • Chen X, Zhang X, Cai H, et al. Targeting USP9x/SOX2 axis contributes to the anti-osteosarcoma effect of neogambogic acid. Cancer Lett. 2020;469:277–286. doi: 10.1016/j.canlet.2019.10.015.
  • Sun R, Zhang HM, Chen BA. Anticancer activity and underlying mechanism of neogambogic acid. Chin J Nat Med. 2018;16(9):641–643.
  • Hatami E, Jaggi M, Chauhan SC, et al. Gambogic acid: a shining natural compound to nanomedicine for cancer therapeutics. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188381. doi: 10.1016/j.bbcan.2020.188381.
  • He H, Lu Y, Qi J, et al. Adapting liposomes for oral drug delivery. Acta Pharm Sin B. 2019; 9(1) :36–48. doi: 10.1016/j.apsb.2018.06.005.
  • Large DE, Abdelmessih RG, Fink EA, et al. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv Drug Deliv Rev. 2021;176:113851. doi: 10.1016/j.addr.2021.113851.
  • Kanwal U, Irfan Bukhari N, Ovais M, et al. Advances in nano-delivery systems for doxorubicin: an updated insight. J Drug Target. 2018;26(4):296–310. doi: 10.1080/1061186X.2017.1380655.
  • Ma S, Li M, Liu N, et al. Vincristine liposomes with smaller particle size have stronger diffusion ability in tumor and improve tumor accumulation of vincristine significantly. Oncotarget. 2017;8(50):87276–87291. doi: 10.18632/oncotarget.20162.
  • Bulbake U, Doppalapudi S, Kommineni N, et al. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12. doi: 10.3390/pharmaceutics9020012.
  • Park J-H, Cho H-J, Yoon HY, et al. Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery. J Control Release. 2014;174:98–108. doi: 10.1016/j.jconrel.2013.11.016.
  • Li Y, Duy Le TM, Nam Bui Q, et al. Tumor acidity and CD44 dual targeting hyaluronic acid-coated gold nanorods for combined chemo- and photothermal cancer therapy. Carbohydr Polym. 2019;226:115281. doi: 10.1016/j.carbpol.2019.115281.
  • Zhang Q, Deng C, Fu Y, et al. Repeated administration of hyaluronic acid coated liposomes with improved pharmacokinetics and reduced immune response. Mol Pharm. 2016;13(6):1800–1808. doi: 10.1021/acs.molpharmaceut.5b00952.
  • Li J, Li M, Tian L, et al. Facile strategy by hyaluronic acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and enhanced breast cancer therapy. Int J Pharm. 2020;578:119122. doi: 10.1016/j.ijpharm.2020.119122.
  • Tang X, Sun J, Ge T, et al. PEGylated liposomes as delivery systems for gambogenic acid: Characterization and in vitro/in vivo evaluation. Colloids Surf B Biointerfaces. 2018;172:26–36. doi: 10.1016/j.colsurfb.2018.08.022.
  • Luo Q, Lin T, Zhang CY, et al. A novel glyceryl monoolein-bearing cubosomes for gambogenic acid: Preparation, cytotoxicity and intracellular uptake. Int J Pharm. 2015;493(1-2):30–39. doi: 10.1016/j.ijpharm.2015.07.036.
  • Mo L, Song JG, Lee H, et al. PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure. Nanomedicine. 2018;14(2):557–567. doi: 10.1016/j.nano.2017.12.003.
  • Doddapaneni R, Patel K, Owaid IH, et al. Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer. Drug Deliv. 2016;23(4):1232–1241. doi: 10.3109/10717544.2015.1124472.
  • Yu Q, Zhang B, Zhou Y, et al. Co-delivery of gambogenic acid and VEGF-siRNA with anionic liposome and polyethylenimine complexes to HepG2 cells. J Liposome Res. 2019;29(4):322–331. doi: 10.1080/08982104.2018.1473423.
  • Liu SJ, et al. Preparation of neogambogic acid nanoliposomes and its pharmacokinetics in rats. J Coll Physicians Surg Pak. 2018;28(12):937–940.
  • Wang F, Ye X, Wu Y, et al. Time interval of two injections and First-Dose dependent of accelerated blood clearance phenomenon induced by PEGylated liposomal gambogenic acid: the contribution of PEG-Specific IgM. J Pharm Sci. 2019;108(1):641–651. doi: 10.1016/j.xphs.2018.10.027.
  • Cheng Y, He W, He Y. Gleditsia saponin C induces A549 cell apoptosis via caspase-Dependent Cascade and suppresses tumor growth on xenografts tumor animal model. Front Pharmacol. 2017;8:988. doi: 10.3389/fphar.2017.00988.
  • Tandon V, Moreno R, Allmeroth K, et al. Dual inhibition of HSF1 and DYRK2 impedes cancer progression. Biosci Rep. 2023; 43(1):BSR20222102. doi: 10.1042/BSR20222102.
  • Chen R, Zhang H, Liu P, et al. Gambogenic acid synergistically potentiates bortezomib-induced apoptosis in multiple myeloma. J Cancer. 2017;8(5):839–851. doi: 10.7150/jca.17657.
  • Morelos-Garnica L-A, Guzmán-Velázquez S, Padilla-Martínez I-I, et al. In silico design and cell-based evaluation of two dual anti breast cancer compounds targeting bcl-2 and GPER. Sci Rep. 2023;13(1):17933. doi: 10.1038/s41598-023-43860-x.
  • Haghighi ZMS, Tabatabaei T, Rafigh M, et al. Human papillomavirus maybe is a critical player in the regulation of chemoresistance related factors (P53, Rb, TWIST, bcl-2, Bcl-XL, c-IAP2, cytochrome C, and caspase 3) in breast cancer. Pathol Res Pract. 2023;248:154653. doi: 10.1016/j.prp.2023.154653.
  • McManus MJ, Franklin JL. Dissociation of JNK activation from elevated levels of reactive oxygen species, cytochrome c release, and cell death in NGF-Deprived sympathetic neurons. Mol Neurobiol. 2018;55(1):382–389. doi: 10.1007/s12035-016-0332-2.
  • Hormozi M, Ghoreishi S, Baharvand P. Astaxanthin induces apoptosis and increases activity of antioxidant enzymes in LS-180 cells. Artif Cells Nanomed Biotechnol. 2019;47(1):891–895. doi: 10.1080/21691401.2019.1580286.
  • Yu H, Cui Z, Yu P, et al. pH- and NIR Light-Responsive micelles with Hyperthermia-Triggered tumor penetration and cytoplasm drug release to reverse doxorubicin resistance in breast cancer. Adv Funct Materials. 2015;25(17):2489–2500. doi: 10.1002/adfm.201404484.
  • Jacinto TA, Rodrigues CF, Moreira AF, et al. Hyaluronic acid and vitamin E polyethylene glycol succinate functionalized gold-core silica shell nanorods for cancer targeted photothermal therapy. Colloids Surf B Biointerfaces. 2020;188:110778. doi: 10.1016/j.colsurfb.2020.110778.
  • Yi K, Kong H, Zheng C, et al. A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy. Biomaterials. 2023;302:122349. doi: 10.1016/j.biomaterials.2023.122349.
  • Nguyen VD, Zheng S, Han J, et al. Nanohybrid magnetic liposome functionalized with hyaluronic acid for enhanced cellular uptake and near-infrared-triggered drug release. Colloids Surf B Biointerfaces. 2017;154:104–114. doi: 10.1016/j.colsurfb.2017.03.008.
  • Chen Y-F, Shiau A-L, Chang S-J, et al. One-dimensional poly(L-lysine)-block-poly(L-threonine) assemblies exhibit potent anticancer activity by enhancing membranolysis. Acta Biomater. 2017;55:283–295. doi: 10.1016/j.actbio.2017.04.009.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.